The most successful approach combines nutritional optimization, structured resistance training, adequate recovery, and intelligent dose management
Researchers believe several mechanisms may contribute to these observations
Recent clinical trials have shown that dual and triple agonists targeting these pathways can lead to superior reductions in body weight and liver fat compared to GLP-1R mono-agonists, with a comparable safety profile [16,17,18,19,20,21,22]
New England Journal of Medicine, 375 ,
The statistics on this page reflect aggregate survey and government data as of July 2026 and should not be taken as a guarantee of coverage for any individual
Noom also offers what it calls microdosing GLP-1s, in which tiny doses of GLP-1 medications are provided to help the body adjust gradually, with the goal of reducing side effects